Common genetic variation in the prothrombin gene, hormone therapy, and incident nonfatal myocardial infarction in postmenopausal women.
Genetic variants in coagulation factors are associated with myocardial infarction and may modify the association between hormone therapy and cardiovascular disease risk. This study assessed whether common variation in the prothrombin gene was associated with incident nonfatal myocardial infarction in postmenopausal women and whether this association differed according to current estrogen use. Eight variants representing 98% of common prothrombin variants were selected using publicly available genomic variation data. These variants and the functional G20210A variant were genotyped and used to infer haplotypes in a population-based Washington State case-control study of postmenopausal Caucasian women (1995-1999; 273 cases and 788 controls). Women carrying a nonsynonymous polymorphism in exon 6 (C5467T) had an increased risk of myocardial infarction (for each additional copy, relative to women with one fewer copy, odds ratio = 1.4, 95% confidence interval: 1.0, 1.8). Prothrombin haplotypes were also associated with myocardial infarction (with minimal adjustment, global p = 0.056; with full adjustment, p = 0.034). Associations between haplotypes and myocardial infarction were similar among users of hormone therapy and nonusers (global p = 0.61), though statistical power was limited. These preliminary results suggest that common genetic variants in the prothrombin gene or other variants in linkage disequilibrium are associated with myocardial infarction in postmenopausal women.
Hindorff
Lucia A
LA
Department of Epidemiology, School of Public Health, University of Washington, Seattle, WA 98101, USA. lah@u.washington.edu
Psaty
Bruce M
BM
Carlson
Christopher S
CS
Heckbert
Susan R
SR
Lumley
Thomas
T
Smith
Nicholas L
NL
Lemaitre
Rozenn N
RN
Rieder
Mark J
MJ
Nickerson
Deborah A
DA
Reiner
Alexander P
AP
D000368:Aged; D016022:Case-Control Studies; D016009:Chi-Square Distribution; D015914:Estrogen Replacement Therapy / Q000009:adverse effects; D005260:Female; D020022:Genetic Predisposition to Disease; D014644:Genetic Variation; D006239:Haplotypes; D006801:Humans; D015810:Linkage Disequilibrium; D009203:Myocardial Infarction / Q000453:epidemiology* / Q000235:genetics*; D011110:Polymorphism, Genetic; D017698:Postmenopause; D011516:Prothrombin / Q000235:genetics*; D012307:Risk Factors
D011516:Prothrombin